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Breast cancer (BC) is the most common malignancy and the second cause of cancer-
specific death in women from high-income countries. Recently, gut microbiota dysbiosis
emerged as a key player that may directly and/or indirectly influence development,
treatment, and prognosis of BC through diverse biological processes: host cell
proliferation and death, immune system function, chronic inflammation, oncogenic
signalling, hormonal and detoxification pathways. Gut colonisation occurs during the
prenatal period and is later diversified over distinct phases throughout life. In newly
diagnosed postmenopausal BC patients, an altered faecal microbiota composition has
been observed compared with healthy controls. Particularly, β-glucuronidase bacteria
seem to modulate the enterohepatic circulation of oestrogens and their resorption,
increasing the risk of hormone-dependent BC. Moreover, active phytoestrogens, short-
chain fatty acids, lithocholic acid, and cadaverine have been identified as bacterial
metabolites influencing the risk and prognosis of BC. As in gut, links are also being
made with local microbiota of tumoural and healthy breast tissues. In breast microbiota,
different microbial signatures have been reported, with distinct patterns per stage and
biological subtype. Total bacterial DNA load was lower in tumour tissue and advanced-
stage BC when compared with healthy tissue and early stage BC, respectively.
Hypothetically, these findings reflect local dysbiosis, potentially creating an environment
that favours breast tumour carcinogenesis (oncogenic trigger), or the natural selection
of microorganisms adapted to a specific microenvironment. In this review, we discuss
the origin, composition, and dynamic evolution of human microbiota, the links between
Frontiers in Microbiology | www.frontiersin.org 1 February 2021 | Volume 12 | Article 584332
fmicb-12-584332 February 22, 2021 Time: 17:33 # 2
Alpuim Costa et al. Human Microbiota and Breast Cancer
gut/breast microbiota and BC, and explore the potential implications of metabolomics
and pharmacomicrobiomics that might impact BC development and treatment choices
toward a more personalised medicine. Finally, we put in perspective the potential
limitations and biases regarding the current microbiota research and provide new
horizons for stronger accurate translational and clinical studies that are needed to better
elucidate the complex network of interactions between host, microorganisms, and drugs
in the field of BC.
Keywords: breast cancer, microbiota, microbiome, dysbiosis, metabolomics, pharmacomicrobiomics,
personalized medicine, review
INTRODUCTION
Breast cancer (BC) is the most common malignancy and
the second cause of cancer-specific death in women from
high-income countries. BC incidence and mortality rates vary
greatly worldwide. According to global cancer statistics from
the International Agency for Research on Cancer (IARC), over
2 million new cases and 600 thousand deaths from BC were
documented in 2018 (Ferlay et al., 2018). The 5 year overall
survival for BC is 98% for localised disease, 84% for regional
disease, but only 23% for distant disease (Saraiva et al., 2017).
The most relevant known BC risk factors include exposure
to endogenous and exogenous oestrogens, high breast density,
history of atypical hyperplasia, lifestyle factors, such as the
Western-style diet, obesity and alcohol consumption, and genetic
susceptibility (Cardoso et al., 2019).
Current evidence points to other clues for a complementary
mechanism of non-hereditary risk of BC. Infectious agents
are known to be the third most important risk factor, after
tobacco and obesity, contributing to 15–20% of cancer incidence
(Garrett, 2015; Banerjee et al., 2018). Gut microbiota is an
emerging field of research, that is being associated with cancer,
through direct and indirect interference in diverse biological
processes: host cell proliferation and death, immune system
function, chronic inflammation, oncogenic signalling, hormonal
and detoxification pathways. Better understanding about this
nested and complex interplay between the host and its own
microbes has provided important data about how gut microbiota
plays a crucial role on the development, treatment and prognosis
of cancer, in particularly BC (Garrett, 2015; Roy and Trinchieri,
2017; Banerjee et al., 2018; Dart, 2019; Alpuim Costa et al.,
2020a). For example, a distinct local and/or intestinal microbiota
signature may contribute to BC development and an “infected”
tumour microenvironment can provide a special fertile habitat
for cancer and its stromal cells.
Most BC patients are diagnosed in initial stages when
the goal of treatment is cure. In early and locally advanced
BC a multimodal approach is frequently used, incorporating
surgery, radiotherapy and systemic therapy (Cardoso et al.,
2019). According to real-world and clinical trial data, metastatic
BC has a highly variable clinical course, with some patients
dying a few months after diagnosis and others surviving more
than 10 years. Therefore, the primary goals of treatment
are to prolong survival and ameliorate the quality of life
(Saraiva et al., 2017; Cardoso et al., 2019). Even with standardised
treatment protocols, patients do not respond in similar ways,
reflecting the heterogeneity of each individual, their unique
BC features, and tumour microenvironment (Cardoso et al.,
2019). However, little is still known about why analogous
molecular subtypes have different clinical courses, and there
is insufficient data regarding predictive factors of response
to available treatments for BC, beyond targeted therapies for
hormonal and human epidermal growth factor 2 (HER2)
receptors, programmed death-ligand 1 (PD-L1), and some
somatic or germline driver mutations (Cardoso et al., 2019).
Among these factors, the human microbiota could be a crucial
piece of the puzzle to better anticipate individual BC risk and
prognosis, pharmacokinetics, pharmacodynamics, and clinical
efficacy (Roy and Trinchieri, 2017).
In this review, we discuss concepts related to the origin,
composition, and evolution of human microbiota throughout
life, the links between gut/breast microbiota and BC,
and explore potential implications of metabolomics and
pharmacomicrobiomics that might impact BC risk, prognosis,
and possibly treatment choices toward a more personalised
medicine. Finally, we put in perspective the potential limitations
and biases regarding the current microbiota research and provide
insights for new and more robust studies in this promising and
challenging field.
DISCUSSION
Gut Microbiota—Origin and Dynamic
Evolution During the Human Life Cycle
Colonisation of the gut with microbes early in life is essential
for the development of newborn’s immune system, metabolic
function and potentially future health. There is accumulating
evidence that intrauterine human foetal environment is
not sterile and that placental microbial flora includes non-
pathogenic commensal microbes of phyla Tenericutes,
Firmicutes, Bacteroidetes, Proteobacteria, and Fusobacteria
(Aagaard et al., 2014). A study in 50 women undergoing non-
emergency caesarean sections reported that meconium and
amniotic fluid microbiota were dominated by reads that mapped
to Pelomonas puraquae and typical skin commensals, including
Propionibacterium acnes and Staphylococcus spp., respectively. It
was also demonstrated that bacterial DNA and short-chain fatty
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acids (SCFA) were present in utero, with a potential contribution
to foetal immune system development (Stinson et al., 2019).
This “in utero colonisation” contribute to a possible heritage of
mother’s microbiota.
Immediately after birth, newborns experience rapid
colonisation by other microorganisms, from their mothers and
surrounding environment. Vaginally delivered babies acquire
bacteria resembling maternal vaginal microbiota (predominantly
Lactobacillus and Prevotella), whereas those born by caesarean
acquire bacteria resembling the skin microbiota (mainly
Staphylococcus spp.) (Stewart et al., 2018).
The evolution of gut microbiota develops in three different
phases that occur throughout childhood: during the first year
of life, the developmental phase, is when most microbial
composition and diversity is defined if breastfed, as breast milk
has higher levels of Bacteroides spp. and is associated with
increased gut diversity and faster maturation; a transitional phase
during the second year of life, with a contribution of different
factors such as household exposures (e.g., siblings and furry pets),
antibiotics and chronic conditions (e.g., asthma, allergies); and
a stable phase on the third year of life and beyond that persists
in adulthood and can be slightly modified by diet, lifestyle and
diseases. In addition, geographic location is crucial for microbiota
development, namely if the child is born in an urban or rural
environment (Stewart et al., 2018).
After 65 years of age, microbiota enters a less diversified
and stable state, resembling modifications observed in dysbiotic
patients. This might contribute to the appearance of some
diseases associated with ageing. In fact, it may reflect the
cumulative impact related to lifestyle on the diversity of flora
(Maynard and Weinkove, 2018).
Gut Microbiota Composition, Diversity,
Resilience, and Dysbiosis Concepts
Commensal microbiota is composed of microorganisms
(archaea, protozoa, fungi, viruses, bacteria) that colonise
gastrointestinal tract and other areas of the body. Human
intestinal microbiota is estimated to contain 1013 bacterial cells,
10 times the number of human cells in the body. Bacterial
load, along with species diversity, increase from the stomach
to the colon, creating a complex microbial ecosystem (Roy and
Trinchieri, 2017; Sommer et al., 2017; Stewart et al., 2018).
For microbiota analysis, it is important to know the principal
concepts that allow us to understand the differences between
a homeostatic and a dysbiotic microbiota (α and β-diversity).
Alpha-diversity can be described as the richness of microbes
present in the gut and can be calculated by Operational
Taxonomic Units (OTU) count (which means the number of
different species in the gut) and Shannon index (which measures
how evenly the microbes are distributed in the gut). β-diversity
is used to compare samples and assesses how different the
microbial community is from one environment to another, like
a microbiological fingerprint (Sommer et al., 2017).
Microbiota holds the capacity of self-regeneration, known as
resilience, explained by the ability to restore its homeostasis after
an external disorder (e.g., infections or antibiotic treatment).
These modifications can be a pulse perturbation (present in a
short period of time as antibiotic intake), or a press disturbance
(continuous maintained process for an extended period of time,
at a constant level, such as permanent diet changes or moving to
another location) (Sommer et al., 2017).
Moreover, it is crucial to understand that resilience of
microbiota depends on three variables for dynamic stability:
time (remains the same microbiota composition through time
and in response to perturbances), taxonomic groups (persistence
of groups through perturbations or over time) and functional
groups (although species and taxonomic groups may change, the
functional properties of the microbiota remain the same). Only
when an accumulated stress threshold is exceeded, a shift from
homeostasis to a new balance occur (Sommer et al., 2017).
Resilience comprises four components: resistance, latitude,
precariousness, and panarchy. Resistance is the capacity to
remain the same during an external perturbation. Latitude
can be defined by the maximum extent that a system can be
pushed by a perturbation before the self-renewal capacity is lost.
Precariousness comprehends the distance between initial state
of equilibrium and a threshold of non-return. Finally, panarchy
refers to how the intrinsic organisational state of microbiota can
cope with stress (Sommer et al., 2017).
However, in some cases, after a perturbation, microbiota
cannot remain resilient, which leads to a new equilibrium state,
often named “dysbiosis.” Dysbiosis is a term that describes a
diseased state of intestinal microorganism communities, which
conducts to an intestinal-microbial imbalance in the host.
Commonly, it is associated with a reduction of α-diversity and
a low-grade of spontaneous inflammation of the mucosal barrier.
That is why this condition correlates with a wide range of human
diseases and can occasionally develop a state of high resilience to
external perturbations (Sommer et al., 2017).
Alpha and β-diversity of microbiota are drivers of resilience
potential. There are four mechanisms related to resilience
capacity: dispersal, diversification, drift and selection. As an
example, the mode of delivery (vaginal or caesarean) can cause
dispersal (due to the impact on maternal-foetal transmission
of microbiota), but also selection (through enhancement or
decrement of the pool of microorganisms that foetus can select
from). Therefore, dispersal means a new genetic variation,
either by mutations or by introduction of a new organism.
Diversification stands for migration of organisms through space.
Drift corresponds to stochastic changes that can occur over time.
Finally, selection has the same meaning as in nature, the survival
of the fittest (Sommer et al., 2017).
Interplay Between Gut and Breast
Microbiota With Breast Cancer
Gut dysbiosis appears to be associated with increased risk of
developing inflammatory, autoimmune, and malignant diseases,
including BC. Dysbiosis can potentially favour oncogenesis and
tumour progression and affect responses and toxicity profile of
antineoplastic agents (Dzutsev et al., 2015; Lobionda et al., 2019;
Nogueira and Shoenfeld, 2019).
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Although current knowledge of links between microbiota and
BC are still scarce, it is already possible to perceive several
steps of this intriguing interaction. First, we must understand
gut microbiota as if it were a metabolite-secreting gland with
paracrine and systemic effects. For local metabolites, the classic
example is related to microbiota influence on the transition from
dysplasia to carcinoma. For systemic metabolites, their effect on
distant cells is comparable to the action of hormones on their
effector organs. Second, these hormone-like metabolites play an
integral role in modulating various aspects of host physiology
involving factors that comprise the “Hallmarks of Cancer.”
Third, the cancer microenvironment per se can enhance the
procarcinogenic activity of microbiota (Hanahan and Weinberg,
2011; Fulbright et al., 2017).
Breast Cancer Microbiota and Normal Breast Tissue
Microbiota
Microbiota of human breast tissue is diverse and distinct
from other areas of the organism regardless of the sample
site within the breast, age, geographical area and pregnancy
history. Diversity of local breast flora is not comparable to
other microbial compartments (e.g., gut, skin, vagina). The
unique breast microbiota pattern consists, in decreasing order,
of Proteobacteria, Firmicutes, Actinobacteria, and Bacteroidetes.
Although breast tissue microbiota has only recently began been
evaluated, the presence of specific microbiota in human milk
has already been known for several years. Also, composition of
human milk microbiota seems to be similar to breast microbiota:
Proteobacteria is the most abundant phylum, followed by the
others phyla (Costantini et al., 2018; Zhang et al., 2020).
Bacterial microbiota of breast tissue and breast milk influences
development of healthy infant gut microbiota and women’s
health. Thus, breast dysbiosis may lead to lactational mastitis
and can further influence metabolic development during
breastfeeding period, adequate microbial colonisation, immune
system maturation and infant growth. An example of this is
the presence of butyrate-producing bacteria in human milk,
such as Roseburia spp., Coprococcus spp., and Faecalibacterium
prausnitzii. These genera can modulate the risk of childhood
obesity, allergic diseases, and cancer (Prentice et al., 2019; Zhang
et al., 2020).
Despite some controversy, current evidence supports that
microbiota of human BC tissue is different from normal
paired tissue. It is not known whether these findings reflect
local dysbiosis, creating an environment that favours breast
tumour formation (oncogenic trigger), or the natural selection
of microorganisms adapted to a microenvironment rich in fatty
acids and other local metabolites.
A study found that Methylobacterium radiotolerans was
relatively abundant in oestrogen positive tumour tissue, and
Sphingomonas yanoikuyae was relatively more prevalent in
paired normal tissue. Moreover, total bacterial DNA load
was lower in tumour tissue and advanced-stage BC when
compared with healthy tissue and early stage BC, respectively.
Additionally, lower baseline levels of antibacterial response
gene expression in tumoural vs. healthy breast tissue was
observed (Xuan et al., 2014). Another study pointed out for
significant differences between sentinel cancer lymph nodes
and normal samples for the presence of M. radiotolerans
(Yazdi et al., 2016). However, abundance of this bacteria in BC
was countered in another investigation (Wang et al., 2017).
In an Asiatic cohort of patients, an increased representation
of genus Propionicimonas and the families Micrococcaceae,
Caulobacteraceae, Rhodobacteraceae, Nocardioidaceae, and
Methylobacteriaceae was observed in BC tissues. Nevertheless,
caution should be taken on extrapolation for a Western
population (Meng et al., 2018). In a Canadian study, it was
reported that adjacent normal tissue of women with BC had a
higher relative abundance of Bacillus, Enterobacteriaceae, and
Staphylococcus, compared to normal breast tissue of healthy
controls (Urbaniak et al., 2016). The different β-diversity between
BC and healthy controls was also confirmed in nipple aspirate
fluid (NAF), which may have a potential role in carcinogenesis.
It was noticed that there were differences in the composition
of microbiota and in functional properties associated with
identified bacteria (Chan et al., 2016).
Conversely to previous data, a study with a Mediterranean
population found more similarities than differences between
tumours and adjacent normal tissues. Yet, supporting
the variability, it was determined for the first time the
presence of genus Ralstonia, phylum Proteobacteria,
as the most abundant genus found in breast tissue.
Following Ralstonia in terms of abundance, the presence
of genera Methylobacterium and Sphingomonas in phylum
Proteobacteria was confirmed consistent with previous studies
(Costantini et al., 2018).
These findings may reflect the influence of bacteria and/or
their components in local immune microenvironment,
highlighting unrecognised links between breast dysbiosis
and BC that might exist.
Gut Microbiota as a Metabolite-Secreting Gland With
Effects on Breast Tissue
Gut microbiota metabolises and secretes hormone-like bioactive
compounds that modulate BC risk, such as reactivated
oestrogens, active phytoestrogens, SCFA, lithocholic acid
(LCA) and cadaverine.
Plottel and Blaser defined human estrobolome as “the
aggregate of enteric bacterial genes whose products are capable
of metabolising oestrogens” (Plottel and Blaser, 2011). An
important role of intestinal microbiota is the modulation of
systemic oestrogens, as microbes and its’ metabolites affect
enterohepatic circulation of oestrogens and their resorption.
Theoretically, an estrobolome enriched with enzymes such as
β-glucuronidase (BGUS), which is produced by many intestinal
bacteria, could play a major role in the deconjugation of
xenobiotics and sexual hormone oestrogens. This leads to their
reuptake via enterohepatic pathway and, therefore, increases
the time they remain in the body. In particular, resorption
of free oestrogen produced by BGUS may increase the risk
of hormone-dependent BC in women. The bacterial genera
Escherichia and Shigella, members of the phylum Proteobacteria,
have BGUS activity. It is likely that bacterial composition of
estrobolome is affected by host factors (e.g., age and ethnicity),
as well as environmental influences throughout life, including
diet, alcohol and use of antibiotics, which can exert selective
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pressures on bacterial populations. Some of these factors
were also independently associated with increased risk of BC
(Plottel and Blaser, 2011; Kwa et al., 2016). A population-
based case-control pilot study in postmenopausal women showed
that those with BC had a statistically significant modified
composition (β-diversity) and lower oestrogen-independent
α-diversity, which means less microbial richness and diversity
(Goedert et al., 2015).
Hence, oestrogen metabolism–gut microbiota axis
dysfunction combined with underlying individual variations
in oestrogen levels may contribute to an increased risk of
hormone-driven malignancies, including BC. In the future,
interventions involving the use of prebiotics, probiotics,
symbiotics, and/or antimicrobial agents may be considered.
These therapeutic strategies can be specifically designed to
modulate intestinal bacterial populations with BGUS activity
to decrease the risk of oestrogen-related BC, or after cancer
diagnosis, become complementary treatments (Plottel and
Blaser, 2011; Kwa et al., 2016).
From another perspective, specific types of intestinal bacteria
are able to metabolise phytoestrogens (e.g., isoflavones and
lignans) and convert them into active metabolites that can protect
against BC. Interventional studies have shown that the ability
of some individuals’ intestinal microbiota to convert isoflavones
and lignans into equol and enterolignans, respectively, may
result in a reduced risk of hormone-dependent diseases, such
as BC. In addition, some isoflavones are absorbed only in the
colon after being metabolised by the intestinal microbiota. Soy
isoflavones are composed of daidzine, genistin and glycitine,
and their absorption is highly dependent on β-glucosidase-
producing bacteria (e.g., lactic acid bacteria). Due to the activity
of this enzyme, daidzine is transformed into daidzein, which is
converted into dihydrodaidzein. The latter metabolite is usually
transformed into O-desmethylangolensin (O-DMA), but in a
smaller percentage of the population it is converted to 7-
hydroxy- 3-[49-hydroxyphenyl]-chroman (equol). However, not
all individuals consuming isoflavones produce equol. Generally,
20–30% of Western population convert this isoflavone to equol
(as opposed to 50–60% of Asian population) (Yuan et al., 2007;
Poluzzi et al., 2014; Gaya et al., 2016).
In terms of beneficial effects and when comparing all
isoflavones and their metabolites, equol is the most potent
estrogenic metabolite, owing to its higher affinity for oestrogen
receptors, unique antiandrogenic properties and superior
antioxidant activity. The antioxidant potential of equol may
be a result of its non-planar structure, which provides higher
flexibility for conformational changes and allows better
penetration into the membrane. Furthermore, it can prevent
oxidative damage in situ, as opposed to other isoflavones, that
hold a more rigid structure (Yuan et al., 2007). Most of equol-
producing bacteria isolated belong to Coriobacteriaceae family,
such as genera Adlercreutzia, Assacharobacter, Eggerthella,
Enterorhabdus, Paraeggerthela, and Slackia. Among these,
species such as Adlercreutzia equolifaciens, Asaccharobacter
celatus, Enterorhabdus mucosicola, Slackia isoflavoniconvertens,
and S. equolifaciens are reported to be equol producers
(Yuan et al., 2007).
In the gut, bacterial fibre fermentation results in generation
of free fatty acids (FFAs) of various chain lengths, a class of
nutrients which are sensed by specific membrane-bound FFA
receptors (FFARs), expressed exclusively throughout gut. In
particular, FFAR1 (GPR40) and FFAR4 (GPR120) are activated
by medium and long-chain saturated and unsaturated FFAs,
while FFAR2 (GPR43) and FFAR3 (GPR41) are activated by
SCFA, mainly acetate, butyrate, and propionate. FFARs have an
important role on physiological functions such as production
of peptide YY, glucose stimulated-insulin secretion, regulation
of inflammatory mediators, leptin production, among others
(Thirunavukkarasan et al., 2017).
Emerging data suggest a role of these receptors in normal
and pathological conditions, including BC. It has been proposed
that FFAR2 and FFAR3 might participate in tumour suppression
through propionate and butyrate, influencing cell proliferation
and inducing apoptosis (Thirunavukkarasan et al., 2017). In a
study with BC cells lines, evaluating the interplay between FFARs
and propionate and butyrate, it was observed that FFAR2 could
increase the levels of E-cadherin in mesenchymal-like cells but
not on epithelial-like cells, which suggests this receptor might
convert cells to an epithelial phenotype, impacting epithelial-
mesenchymal transition (EMT) and potentially decreasing risk of
metastases (Thirunavukkarasan et al., 2017). On the other hand,
FFAR3 has been shown to avoid invasion, but with a different
mechanism. FFAR3 relies on decreasing ERK phosphorylation,
affecting MAPK/ERK1/2 pathway, which is responsible for
regulation of transcription factors fundamental for the EMT
process (Thirunavukkarasan et al., 2017). Thus, microbiota can
have a relevant influence in determining invasive phenotypes
of BC, due to the fact that a percentage of bacteria with anti-
inflammatory characteristics, such as Akkermansia muciniphila
and Faecalibacterium prausnitzii, can produce SCFAs in a
relatively abundant quantity (Lukovac et al., 2014). However,
these conclusions should be taken carefully, because this
organoid model experimental study does not consider variables
such as host and tumour microenvironment, namely on the
bioavailability of SCFAs and the expression of FFAR2 and FFAR3.
Generally, bile acids (BAs) are known to be involved in lipid
metabolism, cholesterol elimination, bile flow and cholesterol
biosynthesis. More recently, it was noticed that BAs also
directly or indirectly interfere as a signalling molecule in cell
proliferation, metabolism and differentiation (Hanafi et al., 2018;
Mikó et al., 2018).
BAs are derived from cholesterol and are stored in the
gallbladder. Cholic acid (CA) and chenodeoxycholic acid
(CDCA) are the two most common types of primary BAs.
They are synthesised and conjugated in the liver into bile
salts, such as glycocholic acid (GCA), taurocholic acid (TCA),
glycochenodeoxycholic acid (GDCA), taurochenodeoxycholic
acid (TDCA) and ursodeoxycholic acid (UDCA). Cytotoxicity
of BAs is dependent on their structural formation, while their
hydrophobicity is based on number and position of the hydroxyl
group in the ring structure. UDCA, the most hydrophilic
BA, seems to play a role, mediated by sphingomyelinase, in
proapoptotic signalling in cancer cells, such as gastric, prostate
and colon cancer cells. The most common secondary BAs,
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deoxycholic acid (DCA) and LCA (the most hydrophobic BA),
are synthesised by bacterial microbiota of the small intestine.
These two BAs are produced as a result of deconjugation
and dihydroxylation of primary BAs. Increased serum levels of
hydrophobic BAs, such as CDCA and DCA, have been associated
with colon cancer, gallstones, and other gastrointestinal diseases.
However, DCA or UDCA have no effect on BC cells at normal
range concentrations (Hanafi et al., 2018; Mikó et al., 2018).
On the other hand, LCA has antiproliferative action
in BC. Bacterial enzyme catalysing the formation of LCA
is 7α/β-hydroxysteroid dehydroxylase (baiH). Anaerobic
bacteria, mainly the Clostridiales, are responsible for this
BA transformation. LCA, through Takeda G-protein coupled
receptor (TGR5), exerts antineoplastic effects on BC cells by
inhibiting EMT, endothelial growth factor vascular production,
metastasis formation, induced antitumour immunity and
changes in metabolism. Moreover, bacterial machinery for LCA
biosynthesis is decreased in the early stage BC, and serum levels
of LCA correlate negatively with Ki67 marking index in BC
(Mikó et al., 2018). Although human cells are also capable of
synthesising cadaverine, production of bacterial cadaverine is
dominant over human biosynthesis. Cadaverine is synthesised
from lysine by bacterial enzymes LdcC and CadA. Shigella
flexneri, S. sonnei, Escherichia coli, and Streptococci have been
shown to express cadaverine biosynthetic enzymes. Cadaverine
seems to have effects in cellular proliferation, EMT, cellular
migration, invasion, and tumour infiltration to surrounding
tissues. In addition, cadaverine alters metabolism in BC cells and
reduces proportion of aldehyde dehydrogenase 1 (ALDH1+)
cancer stem cells in 4T1 murine BC cells (Kovács et al., 2019;
Mikó et al., 2019). In a cohort of triple negative BC (TNBC)
patients, cell marker ALDH1 was correlated with aggressive
biology of BC (high histological and nuclear grades) (Nalwoga
et al., 2010). The trace amine-associated receptor-1 (TAAR1),
one of the receptors from which the cadaverine performs
its functions, was already associated with inhibition of BC
growth. In parallel to what was described for LCA, cadaverine is
decreased in BC, most dominantly in early stage (Kovács et al.,
2019; Mikó et al., 2019).
Dynamic Evolution of Gut and Breast Microbiota
Through Breast-Gut Axis
There are many questions that remain unanswered which are
relevant to fully comprehend the relationship between human
microbiota with BC: what is the true origin of breast microbiota?
Is there an established gut-breast axis? What are the links
between gut and breast microbiota and BC oncogenesis–the so-
called “oncobiome”? Some authors advocate a potential role of
bacterial uptake in the intestinal mucosa mediated by dendritic
cells through an endogenous route as the potential source of
breast microbiota; others suggest the existence of bloodstream
transmission of translocated bacteria from intestinal epithelium
that quickly reach the breast (Rescigno et al., 2001; Costantini
et al., 2018; Zhang et al., 2020).
Gut and breast dysbiosis are probably a reflection of
exogenous factors (e.g., hormone replacement therapy, heavy
alcohol use), but also a result of the influence of endogenous
factors related to the host itself (e.g., ethnicity, overweight
and obesity, menopausal state, BRCA1/BRCA2 genetic
mutations), many of them established risk factors for BC
(Cardoso et al., 2019).
Gut microbiota of premenopausal and postmenopausal
women is different and produces distinctive metabolites.
Intestinal microbiota species that act synergistically in
premenopausal period tend to compete with each other in
postmenopausal period. As an example, in postmenopausal
women, a decrease in calcium absorption can trigger a
fierce competition between different species for the same
substrate (Zhao et al., 2019). The data supports a lower
Firmicutes/Bacteroidetes (F/B) ratio and lower relative
abundance of Lachnospira, Roseburia spp. in postmenopausal
women. In contrast, a higher relative abundance of genera
Prevotella, Tolumonas, Parabacteroides, and Bilophila is present
during the postmenopausal period (Santos-Marcos et al., 2018;
Zhao et al., 2019). A comprehensive shotgun metagenomic
analysis confirmed previous data suggesting a difference
between postmenopausal BC patients and healthy controls in
composition and functions of gut microbial community (Goedert
et al., 2015; Zhu et al., 2018). In this study, several bacterial
species were found to be enriched in postmenopausal BC
patients: E. coli, Citrobacter koseri, Acinetobacter radioresistens,
Enterococcus gallinarum, Shewanella putrefaciens, Erwinia
amylovora, Actinomyces spp. HPA0247, Salmonella enterica,
and Fusobacterium nucleatum. In contrast, other species were
less abundant in this subgroup: Porphyromonas uenonis,
Eubacterium eligens, Roseburia inulinivorans, and Lactobacillus
vaginalis. Interestingly, in postmenopausal BC patients there was
a decrease in butyrate-synthesis genes expression, potentially
related to low abundance of butyrate-producing bacteria
(e.g., R. inulinivorans). As mentioned earlier, this may have
contributed to chronic inflammation and increased risk for BC
(Zhu et al., 2018).
Obesity affects more than half of postmenopausal women and
is associated with increased total fat mass and abdominal fat
and decreased lean body mass compared with premenopausal
women, regardless of ageing (Vieira et al., 2017). Percentage
of body fat seems to be intrinsically inversely related to
A. muciniphila abundance in BC patients. Noteworthy, BC
women with high relative abundance of A. muciniphila have
higher levels of Prevotella, Lactobacillus, and lower levels
of Clostridium, Campylobacter and Helicobacter compared to
patients with low abundance of the former (Frugé et al., 2020).
Moreover, the significance of F/B ratio in overweight/obesity is
still controversial across the studies, with numerical variations
in Firmicutes abundance. A recent study reported a decline
in total bacteria load in overweight and obese patients when
compared with normal body mass index (BMI) patients.
A significantly lower number of total Firmicutes, F. prausnitzii,
Blautia spp., and Eggerthella lenta was observed in patients
with overweight/obesity. In the same study, a correlation
between gut microbiota and BC clinical stages/histoprognostic
grades was performed. Percentage and absolute numbers of
Clostridium coccoides cluster, C. leptum cluster, F. prausnitzii were
significantly higher in clinical stage II/III than in clinical stage 0/I,
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while Blautia was associated with a higher histoprognostic grade
(Luu et al., 2017).
Even ethnicity seems to have an important role in BC
risk. African descendants’ patients have a higher probability
of developing more biologically aggressive forms of BC with
lower survival rates such as TNBC molecular subtype (Saraiva
et al., 2017). There are several factors contributing to BC
racial disparities. African women tend to have higher BMI than
Caucasians, and there is a link between obesity and BC, including
TNBC (Carey et al., 2006; Saraiva et al., 2017). Moreover, there
is data suggesting that TNBC in black women has more active
signalling via insulin growth factor receptor type 1 (IGF1),
Wnt/ß-catenin pathways and more ALDH1 expression (Nalwoga
et al., 2010; Saraiva et al., 2017). In addition, there are potential
microbiotic factors that may interact with BC biology. A recent
study identified racial differences in breast microbiota between
non-Hispanic black (NHB) and non-Hispanic white (NHW)
women and also detected distinct microbiota patterns in relation
to stage and BC subtype: genus Ralstonia was most abundant
in BC of NHB woman, whereas family Xanthomonadaceae
was more abundant in BC of NHW women (both belong to
phylum Proteobacteria); phylum Bacteroidetes was significantly
lower among NHB as compared to NHW; enrichment of family
Streptococcaceae in TNBC; higher abundance of genus Bosea
(phylum Proteobacteria) increased as stage advanced (Smith
et al., 2019). However, besides predisposing factors associated
with African ancestry, it is important to reinforce that black-white
disparities in BC may also be explained by demographics and
socioeconomic factors (Curtis et al., 2008).
Gut and breast microbiota might also modulate tumour
microenvironment. The “Hallmarks of Cancer,” proposed by
Hanahan and Weinberg in 2001 and updated in 2011, logically
defined how a normal cell progresses to a tumourigenic
state within a complex neoplastic environment (Hanahan and
Weinberg, 2011). Thus, breast oncogenesis turns out to be a
sequential or concomitant influence of several biological steps
contributing to evolution of normal tissue to dysplasia and
invasive cancer. In this complex interplay, microbiota, being
one of the protagonists of that “local habitat,” seems to have
a (relevant) role in several mechanisms of BC carcinogenesis:
activating signals for aberrant epithelial proliferation; secretion
of growth factors by senescent cells; genome instability and
mutations; perturbations to local metabolic microenvironment;
specific microbes influence angiogenesis and tumour-associated
remodelling of the vasculature; avoiding immune destruction;
tumour-promoting inflammation (Hanahan and Weinberg,
2011; Fulbright et al., 2017).
Bacteria and their metabolites can modulate different
signalling pathways, including the Wnt/ß-catenin. This pathway
has a crucial role in maintenance of adult tissue homeostasis by
regulating cell proliferation, migration, differentiation, survival
and adhesion, and renewal of stem cells (Fulbright et al., 2017;
Sferrazza et al., 2020). Bacteroides fragilis enterotoxin promotes
cleavage of E-cadherin, an intercellular adhesion molecule that
plays a major role in maintaining intestinal epithelial homeostasis
in basal and inflammatory conditions (Rhee et al., 2009;
Fulbright et al., 2017). Fusobacterium nucleatum also leads to
deregulation of this pathway, through adhesin FadA that binds
E-cadherin and promotes cell proliferation (Rubinstein et al.,
2013; Fulbright et al., 2017). As a result of the inactivation
of E-cadherin, there is a nuclear translocation of ß-catenin,
transcription of proto-oncogene c-Myc, and cellular hyperplasia
(Fulbright et al., 2017). Another pathway that may be involved
in chronic inflammation of breast tissue and in BC progression
is related to human papillomavirus (HPV) infection and viral
induction of transcription 3 (STAT3) signalling and consequent
elevation of interleukin 17 (IL-17). These data show that
gut and breast microbiota can activate signals for aberrant
cell proliferation (Zhang et al., 2016). Persistent dysregulation
of the DNA damage response and repair in cells causes
genomic instability. The resulting genetic changes allow pre-
malignant and malignant cells to retain and accelerate the rate
of mutations (Fulbright et al., 2017; Palovcak et al., 2017).
There is evidence that E. coli, Staphylococcus epidermidis, and
E. faecalis have the ability to inflict DNA damage through
production of genotoxins (including colibactin), hydroxyl and
superoxide radicals (Urbaniak et al., 2016; Eslami-S et al., 2020).
In addition, E. coli colibactin can induce senescence-associated
secretory phenotype of growth factors capable of stimulating
cell proliferation and tumour progression (Fulbright et al., 2017;
Chadha et al., 2020).
Perturbations to gut and breast metabolic environment can
also favour or inhibit BC oncogenesis.
As discussed earlier, one of the ways gut and breast microbiota
could influence tumourigenesis is by enhancing local exposure
of breast tissue to a hormonal trigger. Endogenous progesterone
metabolites may provide a new hormonal basis for BC. BC tissue
has elevated 5α-reductase activity, which results in significantly
higher total levels of 5α-pregnanes, especially 5α-pregnane-
3,20-dione (5αP), whereas normal breast tissue produces more
4-pregnenes, especially 3α-hydroxy-4-pregnen-20-one (3αHP).
Thus, local changes in progesterone metabolism, with an
increased 5α-pregnane:4-pregnene (especially 5αP:3αHP) ratio,
may promote BC by stimulating increased cell proliferation
and detachment. Increases in 4-pregnenes may retard these
tumourigenic processes (Wiebe et al., 2000). One of possible local
mechanisms in tumour microenvironment that might lead to
increased production of 5αP is higher levels of Bacillus cereus.
This Gram-positive agent was found to be elevated in BC tissue.
This has already been shown to promote proliferation of tumour
cells in vitro by metabolising progesterone to 5αP (Urbaniak et al.,
2016; Chadha et al., 2020).
Polycyclic aromatic hydrocarbons such as oestrogens and
other hormones are linked to BC development. Metabolic
pathway related to BGUS activity appears to be associated with
increased risk of hormone-dependent BC (Plottel and Blaser,
2011; Kwa et al., 2016). Oestrogen is detoxified by conjugation
with glucuronidate to become soluble. When this conjugated
oestrogen reaches a site with increased BGUS activity, this
enzyme leads to accumulation of biologically active oestrogens
which have a carcinogenic role. Intriguingly, positive BGUS
bacteria are present and increased in local BC microbiota
(even in NAF of BC survivors) (Thompson et al., 2017).
Streptococcus pyogenes is capable of increasing oestrogen levels
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in mammary tissue through BGUS activity (Thompson et al.,
2017). Conversely, S. yanoikuyae has the ability to metabolise
oestrogens locally, potentially constituting a protective factor in
healthy controls opposite to what is observed in patients with
BC (Xuan et al., 2014). In addition to E-cadherin, SCFAs are
considered essential for regulation of intestinal epithelial integrity
and host cellular metabolism. These products are among the most
important of bacterial metabolites and have long been recognised
as relevant substrates for preserving a healthy gut (Chambers
et al., 2018). SCFAs modulate numerous cancer hallmarks, such
as cell proliferation, apoptosis, cell invasion, gene expression, and
metabolism in BC (Mikó et al., 2019). Otto Warburg observed
that cancer express high rates of fermentation in the presence of
oxygen (Warburg et al., 1927). This “Warburg Effect” is linked
to mitochondrial dysfunction and genetic mutations within the
cancer cell (Warburg et al., 1927; Mikó et al., 2019). In this
way, BC cells rely heavily on glucose for energy (Warburg et al.,
1927; Fulbright et al., 2017). In BC cells, SCFAs can be used
directly as energy substrates and in particular butyrate can lead
to oxygen consumption, inhibition of lactate metabolism and
slowed cell proliferation (Fulbright et al., 2017; Mikó et al., 2019).
Furthermore, increases in intracellular butyrate will act as a
histone deacetylase inhibitor, promoting apoptosis and inhibiting
cell proliferation through epigenetic modifications (Fulbright
et al., 2017). As discussed earlier, bacterial machinery for LCA and
cadaverine biosynthesis is decreased in the early stage BC (Kovács
et al., 2019; Mikó et al., 2019).
Moreover, besides metabolic activity, bacteria can interfere
with immune system’s response. Ductal epithelium can detect
microbial-derived signalling through Toll-like receptors (TLR)
and nucleotide-binding oligomerisation domain (NOD)-like
receptors (NLRs). While some TLRs may be procarcinogenic,
such as TLR2-MyD88, others may play a protective role,
inhibiting growth of cancer cells and having potent antitumoural
activity, such as TLR5 (Scheeren et al., 2014; Chan et al., 2016).
As an example, it was demonstrated that S. yanoikuyae could
activate TLR5 using a single polar flagellum as a ligand for TLR5
(Chan et al., 2016). As mentioned earlier, HPV stimulates IL17-
driven inflammation and contributes to an inflammatory and
procarcinogenic microenvironment. Likewise, Alistipes through
IL-6 and STAT3 activation, induces epithelial hyperplasia and
barrier dysfunction (Zhang et al., 2016; Fulbright et al., 2017).
Recently, it was documented that F. nucleatum reaches breast
tissue via haematogenous route and specifically attaches to
breast cells trough a bacterial lectin-host sugar (Fap2-Gal-
GalNAc) interaction. Furthermore, colonisation of breast tissue
by F. nucleatum is secondary to tumour initiation, using Fap2
adhesion to silence cytotoxic immune cells and reduce infiltration
of CD4 + and CD8 + T cells into “infected tumours.” The data
also support that F. nucleatum accelerates tumour growth and
metastatic progression (Parhi et al., 2020).
In another investigation, it was also demonstrated that
Listeria fleischmannii and Neisseria subflava were correlated
with cancer gene expression, mainly genes involved in EMT.
Within the same analysis, Haemophilus influenzae was correlated
with genes representing crucial pathways for tumourigenesis:
G2M checkpoint, E2 signalling, and mitotic spindle assembly.
Interestingly, an increase in the presence of H. influenzae
was found in non-cancerous adjacent samples, suggesting that
oxidative tumour environment is harmful, forcing bacteria to
reside predominantly in surrounding stromal tissue. These
results are in line with previous data demonstrating that
non-cancerous adjacent tissue represents an intermediate state
between healthy and invasive disease (Thompson et al., 2017).
The vascular network is important since tumour persistence
and proliferation depends on an adequate supply of oxygen,
nutrients, and removal of catabolic products. However, links
between microbiota and angiogenesis are limited. Microbiota is
necessary for normal development of vasculature in gut and,
during an infectious process, there is an interaction between
microbiota metabolites and TLR to promote angiogenesis.
However, the same behaviour for tumour-induced angiogenesis
cannot be predicted (Fulbright et al., 2017).
Finally, regarding molecular subtypes, unique and common
BC complete microbiota signatures (bacteria, viruses, fungi, and
parasites) have been identified (Costantini et al., 2018; Smith
et al., 2019). Oestrogen receptor-positive and HER2 positive
diseases share a more similar microbial signature than TNBC
tissues. Main signatures common to all four molecular types
identified were Proteobacteria, Firmicutes, Actinobacteria, and
Bacteroidetes (Costantini et al., 2018).
Gut Microbiota and Its Impact on Breast Cancer
Treatment
Microbiota affects chemo-, hormone-, targeted-, immuno-, and
radio-therapy for BC. In recent years, it has been shown that
gut microbiota may modulate cancer treatments’ efficacy and
adverse effects. On the other hand, it is also apparent that both
cancer itself and anticancer therapies interact with gut microbiota
bidirectionally (Supplementary Material; Panebianco et al.,
2018; Wilkinson et al., 2018; Gately, 2019).
Pharmacomicrobiomics is defined as the effect of microbiome
variations on drug disposition, action and toxicity (ElRakaiby
et al., 2014; Panebianco et al., 2018). Here, we present the most
relevant knowledge to date regarding the impact of microbiota in
drugs frequently used to treat BC patients.
A study reported that under anaerobic conditions, a group
of bacteria from Enterobacteriaceae family have the ability to
inactivate doxorubicin, influencing its bioavailability and toxicity
profile. Raoultella planticola deglycosylates doxorubicin into
7-deoxydoxorubicinol and 7-deoxydoxorubicinolone through
reductive deglycosylation. Degradation of doxorubicin by
Klebsiella pneumoniae and E. coli BW25113 is dependent on
molybdopterin-dependent enzymes (Yan et al., 2018).
Cyclophosphamide, in addition to antimitotic and
antireplicative effects, has immunosuppressive and
immunomodulatory properties. In tumour-bearing mice, it
leads to disruption of intestinal barrier and migration of a set of
Gram-positive species (L. johnsonii, L. murinus, and E. hirae)
to mesenteric and spleen lymph nodes. Subsequently, there
is a generation of inflammatory T helper 17 (Th17) and Th1
lymphocytes. Tumour-bearing mice that were germ-free or
that had been treated with antibiotics against Gram-positive
bacteria revealed a reduction in Th17 responses and resistance
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to cyclophosphamide treatment. Adoptive transfer of Th17
cells partially restored efficacy of this alkylating drug (Viaud
et al., 2013; Panebianco et al., 2018). In a subsequent study,
oral gavage with E. hirae was shown to restore the response to
cyclophosphamide in tumour-bearing antibiotic-treated mice
(Daillère et al., 2016; Panebianco et al., 2018).
Taxanes or taxoids are a closely related group of antineoplastic
agents that stabilise cellular microtubules. Recent investigation
supports the hypothesis that paclitaxel could decrease the
count and capacity of beneficial gut bacteria, interfering with
proper functioning of intestinal barrier and increasing systemic
exposure to bacterial products and metabolites. In this setting,
for example, a decrease in the levels of A. muciniphila can be
a driving factor for systemic inflammation and taxanes-induced
neuropathic pain. In the same study, it was also hypothesised that
L. intestinalis and E. siraeum are inhibitors of the pain phenotype
(Ramakrishna et al., 2019). In a randomised trial to detect the
effect of symbiotics on adverse effects of combined chemotherapy
(including docetaxel), a decrease in diarrhoea, lymphopenia and
febrile neutropenia has been reported. In detail, the symbiotic
preparation included Bifidobacterium breve strain Yakult, L. casei
strain Shirota, and galactooligosaccharides (Motoori et al., 2017;
Panebianco et al., 2018).
Gemcitabine (2′,2′-difluorodeoxycytidine) is a deoxycytidine
analogue which inhibits DNA synthesis. It was found that
bacteria, mainly belonging to the class Gammaproteobacteria,
can metabolise gemcitabine in its inactive form (2′,2′-
difluorodeoxyuridine). This metabolism is dependent on
the expression of a long isoform of bacterial enzyme cytidine
deaminase (CDDL), observed primarily in this class of bacteria.
In a cancer mouse model, gemcitabine resistance caused by
intratumoural Gammaproteobacteria was reversed by co-
administration of ciprofloxacin, thus supporting the role of
these bacteria in the failed response to this drug (Geller et al.,
2017; Panebianco et al., 2018). Mycoplasma spp. (including
M. hyorhinis) colonise tumour tissue in cancer patients. Presence
of this bacteria could be a limiting factor for gemcitabine
efficiency by expressing nucleoside analogue-catabolising
enzymes (pyrimidine nucleoside phosphorylase and CDDL)
(Panebianco et al., 2018).
The importance of microbiota to modulate platinum salts
response was also verified. The mechanisms of action depend
not only on the formation of platinum-DNA adducts which
block DNA replication and stimulate production of reactive
oxygen species (ROS) and oxidative stress, but also on
its ability to stimulate an immune response (Panebianco
et al., 2018). To investigate whether microbiota changes
tumour microenvironment, mice received an antibiotic cocktail
(vancomycin, imipenem, and neomycin) starting 3 weeks before
tumour inoculation and continuing throughout experiment.
Antibiotic treatment affected tumour cytotoxicity shortly after
chemotherapy, preventing platinum-induced DNA damage and
apoptosis after DNA adduct formation by decreasing ROS
production. This effect was documented using both oxaliplatin
and cisplatin, the latter unable to trigger immunogenic cell
death. Hence, data suggest that microbiota modulate platinum
salts genotoxicity independently of an immunogenic response
(Iida et al., 2013; Panebianco et al., 2018). Consistently with this
data, an increase in tumour size and decrease in survival rate was
observed in a mouse model with lung cancer receiving cisplatin
combined with antibiotics, compared to animals receiving
cisplatin alone. In contrast, mice administered with cisplatin
combined with Lactobacillus showed a better response to therapy
(Gui et al., 2015; Panebianco et al., 2018).
5-Fluorouracil (5-FU), 5-fluoro-2′-deoxyuridine (FdUrd)
and 5-trifluorothymidine (F3(d)Thd) are metabolised to
their corresponding active forms, which in turn inhibit
DNA synthesis through thymidylate synthase (TS). Several
studies suggest a selective death of commensal microbiota
after 5-FU administration, allowing expansion of potentially
pathogenic species and a decrease in F/B ratio (Li et al.,
2017; Panebianco et al., 2018). Following 5-FU, an increase
in Clostridium spp., Staphylococcus spp. and E. coli, and a
decrease in Bacteroides spp., Bifidobacterium spp., Lactobacillus
spp., and F. prausnitzii are reported in faecal microbiota
(Panebianco et al., 2018). Furthermore, a study reported
that faecal transplant (FMT) from healthy mice was able
to prevent total body weight loss and colon shortening in
5-FU treated mice (Li et al., 2017). Enzymatic functions of
specific bacteria also have a pivotal role in modifying the
toxic profile of 5-FU and capecitabine (Alexander et al., 2017).
Mycoplasma hyorhinis encodes a thymidine phosphorylase
that significantly restricts cytostatic activity of pyrimidine
nucleoside analogue compounds such as FdUrd and F3(d)Thd
in vitro. Interestingly, the opposite is true for capecitabine
(N4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine) metabolite
5-fluoro-5′-deoxyuridine (5’dFUrd), which is more effective in
the presence of M. hyorhinis, as this prodrug is activated by the
same enzyme (Alexander et al., 2017).
HER2 is amplified or overexpressed in 20–30% of all BC
patients. It has been demonstrated that HER2 positive BC
exhibits sensitivity to HER2 inhibitors, such as trastuzumab,
pertuzumab, and trastuzumab emtansine (Cardoso et al.,
2019; Cardoso et al., 2020; Yi et al., 2020). In a recent work,
patients treated with neoadjuvant trastuzumab, who achieved
pathological complete response (pCR) were characterised
by higher abundance of Clostridiales bacteria and lower
representation of Bacteroidales as compared to those with
residual disease (RD) at surgery. When performing FMT from
pCR and RD patients into recipient mice, it was replicated the
treatment response observed previously in patients, indicating
a causal role for commensal bacteria. Moreover, antibiotics
abrogated trastuzumab benefit in mice, with decreased levels of
Clostridiales bacteria and compromised recruitment of immune
cells in tumour microenvironment (Martina, 2020). There is
data reporting that the combination of Lactococcus lactis or
L. paracasei with trastuzumab improved its efficacy in mice
under vancomycin regimens (Martina, 2020). Furthermore,
there is a case report of successful treatment of refractory
pertuzumab-induced gastrointestinal toxicity with rifaximin,
a non-absorbable oral antibiotic approved for irritable bowel
syndrome with diarrhoea. Rifaximin inhibits small intestinal
bacterial overgrowth and modulates gut microbiota. Following
this pharmacological intervention, patient was able to continue
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and complete the planned treatment without dose reduction or
delay (Soyano et al., 2017).
Regarding hormone therapy, letrozole, an aromatase
inhibitor, was associated with a time-dependent shift in gut
microbiota and a substantial reduction in overall species
and phylogenetic richness. This treatment was correlated
with a relative decrease in all of Bacteroidales OTUs and an
increase in a majority of Firmicutes OTUs including 5 OTUs
identified as Lachnospiraceae, one in family Erysipelotrichaceae,
genus Allobaculum and two in family Ruminococcaceae.
Only four Firmicutes OTUs significantly decreased after
letrozole treatment (two Clostridiales: Ruminococcaceae
and Dehalobacteriaceae).Notably, the shift in microbiota of
letrozole-treated mice after 1 week of treatment was followed
by significantly increased adiposity in second week of the
experiment (Kelley et al., 2016). As mentioned previously,
specific types of bacterial species are able to metabolise
phytoestrogens and convert them into active metabolites
that can protect against BC. There is data supporting that
combination of daidzein with tamoxifen increased protection
against breast carcinogenesis, while the combination of genistein
with tamoxifen has an opposing effect when compared with
tamoxifen alone (Constantinou et al., 2005).
A plethora of immunotherapy options is now part of
treatment armamentarium of several malignancies, including BC
(Alpuim Costa et al., 2020b). New generation immunotherapy
is represented by the blockade of immune checkpoints, such as
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and PD-
(L)1, which are negative regulators of T cell proliferation and
functions (Panebianco et al., 2018). In cancer mouse models,
it was observed that germ-free animals or those treated with
broad-spectrum antibiotics had no response to ipilimumab.
Particularly, Bacteroides thetaiotaomicron and B. fragilis were
identified as responsible for CTLA-4 blockade efficacy through
the induction of a Th1 immune response (Panebianco et al.,
2018; Vétizou et al., 2015). When analysing colitis secondary to
anti-CTLA-4 treatment, there were differences between subjects
prone and resistant to colitis: a higher abundance of bacteria
from the Bacteroidetes phylum, specifically from Bacteroidaceae,
Rikenellaceae, and Barnesiellaceae families, was observed in
patients who did not manifest adverse events (Panebianco et al.,
2018). Furthermore, a paucity of bacterial genetic pathways
involved in polyamine transport and vitamin B biosynthesis has
been found to be associated with an increased risk of developing
ipilimumab-induced colitis (Dubin et al., 2016; Panebianco
et al., 2018). In addition, if vancomycin was administered to
mice with colitis and treated with anti-CTLA-4, they had more
severe manifestation of intestinal disease, while administration
of a common probiotic with Bifidobacterium could alleviate
symptoms, without a detrimental effect on antitumour immunity
(Dubin et al., 2016; Panebianco et al., 2018).
Several recent studies demonstrated an impact of
gut microbiota in mediating response to anti-PD-(L)1
immunotherapy: oral administration of a cocktail of
Bifidobacterium spp. combined with an anti-PD-L1 antibody
almost abolished cancer growth (Sivan et al., 2015); commensal
microbiota with abundance of B. longum, Collinsella aerofaciens,
and E. faecium was associated with anti-PD-1 cancer efficacy
(Matson et al., 2018); higher microbial diversity and increased
levels of Ruminococcaceae in treatment responders and FMT
from responders patients to germ-free animals enhanced
response (Gopalakrishnan et al., 2018); faecal levels of
A. muciniphila directly correlated with anti-PD-1 therapy
efficacy and FMT from responders patients to germ-free or
antibiotic-treated mice improved treatment efficacy (Panebianco
et al., 2018; Routy et al., 2018). Recently, a clinical benefit was
reported in a phase I trial with anti-PD-1 refractory metastatic
melanoma patients who underwent FMT from donors with
complete response after anti-PD-1 monotherapy (Baruch
et al., 2020). In another clinical trial comparing outcomes in
patients with metastatic hormone receptor positive BC who
received eribulin (antitubulin antimitotic agent) with or without
pembrolizumab (anti-PD-1 agent), a shift in the abundance of
Akkermansia and Faecalibacterium after two cycles of therapy
was described. However, alterations were only reported in
patients receiving eribulin (Barroso-Sousa et al., 2020). These
findings require future confirmation in larger cohorts and further
studies in BC are needed to validate microbiota as a predictor of
treatment efficacy.
Similarly to other anticancer treatments that induce
immunogenic cell death, radiotherapy promotes systemic
inflammation (Martina, 2020). Gut microbiota has been
demonstrated to have a role in radiotherapy efficacy and toxicity
(Eslami-S et al., 2020; Martina, 2020). Radiotherapy outcomes
are highly dependent on tumour microenvironment (Poff et al.,
2013; Martina, 2020). In contrast with normal tissue, tumour
microenvironment may involve abnormal metabolism, including
hypoxia, acidosis and necrosis (Duong et al., 2019). Low oxygen
concentration in hypoxic tumour areas can be attractive for
obligate anaerobes (e.g., Clostridium and Bifidobacterium) and
facultative anaerobes (Duong et al., 2019). In fact, hypoxia
cancer cells are three times more resistant to radiotherapy
than well-oxygenated cells (Poff et al., 2013). Two promising
treatments involve the use of hyperbaric oxygen therapy and
nimorazole (antimicrobial with activity against anaerobic
bacteria and protozoa) to reverse the cancer-promoting effects
of tumour hypoxia (Thomson et al., 2014; Bennett et al., 2018).
Furthermore, radiotherapy affects gut microbiota composition
with a potential effect on vitamin D metabolism. Alteration of
serum level of vitamin D may influence radiotherapy response
through mechanisms associated with gut microenvironment,
including immune cell response, bacterial metabolites and
signalling pathways related to vitamin D receptors. Loss of
DNA repair protein 53BP1 results in radioresistance of BC cells.
Interestingly, the active form of vitamin D (25-hydroxyvitamin
D3) stabilises 53BP1 levels in tumour cells, resulting in increased
genomic instability in response to radiation and reduced
cell proliferation (Huang et al., 2019). Gut microbiota is a
double-edged sword for radiation response, with effects that
can be either beneficial and protective or detrimental and
resistant. Lactobacillus sakei, L. acidophilus, L. casei, and
Bifidobacterium spp. are known to have a radioprotective
effect (Huang et al., 2019). In contrast, there are ionising-
radiation-resistant bacteria such as Rubrobacter radiotolerans,
Deinococcus radiodurans R1, R. xylanophilus, Chroococcidiopsis
spp., Hymenobacter actinosclerus, Kineococcus radiotolerans,
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A. radioresistens, Kocuria rosea, and M. radiotolerans (Cox and
Battista, 2005). As described earlier, M. radiotolerans (D10-value
of 1,000 Grey) and A. radioresistens (D10-value of 2,000 Grey)
were found to be relatively abundant in oestrogen positive
BC (including in sentinel lymph node) and postmenopausal
BC patients, respectively (Xuan et al., 2014; Yazdi et al., 2016;
Zhu et al., 2018). Deinococcus radiodurans is an extremely
resilient radioresistant bacteria (D10-value of 10,000 Grey) that
limits DNA damage through efficient mechanisms of proteins
protection against oxidative stress and DNA repair, enhanced by
functional redundancies in both systems (Cox and Battista, 2005;
Slade and Radman, 2011). In the future, further investigation of
what mechanisms make bacteria resistant to radiation could help
improve response to treatments.
Nowadays, despite new modern radiotherapy techniques,
delayed radiation injury can appear with a latency period of a
few months to several decades (Bennett et al., 2016). Recently,
a unique gut microbiota signature was identified in an animal
model of late radiation-tissue injury, capable of increasing
expression of IL-1β, IL-6, and TNF-α. Radiation significantly
reduced the prevalence of Firmicutes and increased abundance
of Akkermansia, Bacteroides, Parabacteroides, Sutterella,
Turicibacter, and of an unclassified genus belonging to RF32
order (Gerassy-Vainberg et al., 2018).
In addition, new treatment combinations were investigated
to explore the effect of probiotics on local BC tissue. However,
it appears that breast microbiota cannot be modified even
with long-term exposure to locally administered probiotics and
therefore, the beneficial effects will be more related to gut
microbiota modulation (Eslami-S et al., 2020).
These pharmacomicrobiomics studies may support the
potential use of gut microbiota analysis to predict patients’
response to treatments, allowing a more personalised
approach based on the microbiota-host-cancer triad. Our
expectancies are that, in the near future, in-depth knowledge
of interactions between therapeutic agents and microbiota will
have a growing interest and impact clinical practice shifting
treatment paradigms.
Potential Limitations and Future Perspectives
Since the advent of the latest next-generation sequencing
(NGS) techniques, such as 16S rRNA and shotgun sequencing,
the understanding of microbiota/microbiome and disease has
been growing at an accelerated rate with promising results.
These new laboratory methods allow deciphering microbiota
at species-level, with high precision, detecting even small but
significant changes.
However, there are still some limitations and biases that
need to be considered. First, there are several confounding
variables which can influence final interpretation, due to the
fact that microbiota is modulated by a wide range of external
factors, such as age, sex, body mass index, type of diet,
and geographical location. In most studies, these confounding
variables are not measured or balanced, and the number of
patients is considered small and unrepresentative, which makes
it difficult to extrapolate the results. Thus, drawing definitive
conclusions of these data is risky, since microbiota has high
heterogeneity between individuals and even within the same
individual (O’Malley and Skillings, 2018).
Another relevant concern is methodological and technical
comparisons between studies since there are different NGS
methods to analyse microbiota (e.g., 16S rRNA and shotgun
metagenome analysis). In some studies, there is a difference
at the genus-level, while in others this variation is found at
a species-level, increasing the difficulty of making inferences
and extrapolations. In addition, statistical and bioinformatics
analysis is not the same across the studies. Sample collection,
preservation, transportation and time to analysis also impact
results and are not, unfortunately, standardised.
With regards to the struggle for comparison between different
studies, there are “top-down” researches, which means that
microbiota is analysed as an ecosystem and, thus, dysbiosis is
described as taxonomic/functional group changes, while that
in “bottom-up” researches the focus is on specific microbial
aspects and their mechanisms, regardless of the community
effect. Based on this, the comparison between these two types
of studies is fallacious and should be done with caution
(O’Malley and Skillings, 2018).
Moreover, many of these studies are performed in vitro,
which makes it difficult to conjecture the same assumptions to
a living organism and to prove causality. Hence, to formulate
inferences of causality, animal studies need to be carried out
with a standardised methodology, such as the following: a group
of gnotobiotic mice (e.g., germ-free mice) is transplanted with
faeces from humans with a certain disease, and another group is
transplanted with faecal material of healthy human participants.
Then, a comparison is made between the two groups, evaluating
signs and symptoms in the group of patients, in order to find
altered mechanisms and dysbiosis.
However, the major drawback remains the fact that the
microbiota is highly variable among individuals with a
particular disease and even in the patient itself, including
during the circadian rhythm. Furthermore, the recipient and
the donor diverge in genetic, anatomical, physiological, and
behavioural components, which may affect the reliability of
causal inference. Therefore, this method may not reflect the real
alterations in microbiota after transplant for gnotobiotic mice
(Walter et al., 2020).
We propose some recommendations and future perspectives
that may be considered in upcoming studies that intend to study
the association of BC with the microbiota, allowing to overcome
some of the limitations aforementioned:
• Design studies based on assumptions validated in previous
studies (if existing) and related to the main objectives
and the study setting (e.g., to determine the difference
of the F/B ratio in patients with BC and a control
group of healthy volunteers or comparison between gut
microbiota profile between locally advanced BC and de
novo metastatic BC patients).
• Stratification of the patients by different subgroups (e.g.,
postmenopausal state, omnivorous vs. vegan diet).
• To define precise inclusion and exclusion criteria in order
to control confounding variables as much as possible (e.g.,
exclude patients with 3 months prior use of antibiotics,
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probiotics, prebiotics, symbiotics, laxatives, proton pump
inhibitors, or Chinese herbal medicine).
• Control the conditions of collection, storage, and transport
of biological samples (e.g., faecal samples stored at −80◦C
or, whenever possible, the collection should be done at the
same timepoint of the day, in order to control individual
circadian variations).
• Generally, bioinformatic analysis should be standardised,
with the intention of validating comparison between
studies. Some research groups have proposed
methods for microbiota standardisation analysis
(Lahti and Shetty, 2017).
• When performing microbiota studies in animal models,
there is a need to transplant faecal material, either
from healthy humans (part of the control group) and
humans with a specific disease (part of the experimental
groups) to gnotobiotic mice. Hence, swith the aim
to evaluate whether the modifications of microbiota
observed in human faeces are reflected in the animal
model, the research should evaluate microbiota
before and after the transplant. Furthermore, animal
models, more similar to humans, as primates and pigs,
should be used in order to produce more validated
inferences.
• Whenever possible, with the intention to prove
reproducibility and replicability, and to understand if
the effect of microbiota modifications is, in fact, biological
or the product of local/community influences, studies
should be performed intercontinentally.
• In relation to the interplay between microbiota and the
BC, it is suggested that the studies take into consideration,
not only the bacterial segment of microbiota but also the
virome (e.g., viral portion of microbiota), mycobiome (e.g.,
fungal portion of microbiota), and metabolomics (chemical
processes concerning metabolites), in order to assess all
the effects and relationships between each member of the
respective microbial ecosystem.
• There is an unmet need to explore, which consists
of possible mechanisms of gut microbiota modulation
through prebiotics, probiotics, symbiotics, antibiotics, or
personalised nutrition and, ultimately, even by faecal
microbiota transplant.
• The capacity to understand the association between gut
microbiota and breast microbiota is still lacking on how
communication between them occurs, how they influence
each other, whether the intestinal microbiota reflects the
breast microbiota or vice versa and whether, modulating the
gut microbiota, there is an echo in the breast microbiota
(breast-gut axis).
• Finally, there is still a need to comprehend what are
the processes that can cause, in some patients, what
is called “cancer brain” or “chemo brain.” Possibly,
exploring the back-and-forth of the gut-brain axis, BC
metabolomics and pharmacomicrobiomics, a clearer and
complementary explanation can be reached (Bajic et al.,
2018; Ma et al., 2019).
Although the microbiota/microbiome is a rapidly evolving
field and of transversal interest to science, there are still profound
grey areas around the real links between BC and the millions
of microbes that are part of the cellular and genetic heritage
of its human host.
CONCLUSION
Microbiota, the “unknown organ,” seems to have a remarkable
impact on our organism. However, the links between BC and
microbiota are complex and not yet fully understood. Gut
and/or breast dysbiosis may contribute or even correspond to a
precursor and facilitator state of breast oncogenic process.
With the use of multi-omics, an astonishing growing
biotechnological area, we believe that it will be feasible, in
the short-term, to demonstrate more precise links between BC
and microbiota and to bring these findings into the clinical
practice. Stronger and accurate translational and clinical studies
are needed to support this rationale and speed access of patients
to a new, fascinating and even more tailored therapeutic avenues.
In the near future, microbiota could be considered a non-
hereditary risk factor for BC, potentially modulated by a
personalised preventive and therapeutic approach. Likewise,
in established BC, the microbiota may be a prognostic and
predictive factor of response to treatment and/or its side
effects. Also, modulation of microbiota can be used to improve
outcomes in BC patients.
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